Previous close | 274.22 |
Open | 272.81 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 272.81 - 284.99 |
52-week range | 262.00 - 426.50 |
Volume | |
Avg. volume | 1,009 |
Market cap | 18.176B |
Beta (5Y monthly) | 0.78 |
PE ratio (TTM) | 28.75 |
EPS (TTM) | 9.49 |
Earnings date | 02 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Explore key insights from Comstock Inc's Q1 2024 earnings, including significant revenue streams, strategic investments, and future financial strategies.
COPENHAGEN, Denmark, April 29, 2024--Genmab A/S (Nasdaq: GMAB) and Pfizer Inc. (NYSE: PFE) announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. This FDA action converts the September 2021 accelerated approval of TIVDAK to a full approval. TIVDAK is the first anti
NEW YORK & COPENHAGEN, Denmark, April 29, 2024--Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) today announced the U.S. Food and Drug Administration (FDA) approves the supplemental Biologics License Application (sBLA) granting full approval for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.